Marjolijn N. Lub–de Hooge

Author

Also Known As

M N Lub-de Hooge, M. N. Lub-De Hooge, M. N. Lub-de Hooge, M.N. Lub-De Hooge, M.N. Lub-de Hooge, MN Lub-de Hooge, Marjolijn N Lub-de Hooge, Marjolijn N. Lub-De Hooge, Marjolijn N. Lub-de Hooge, Marjolijn N. Lub–de Hooge

233

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen Amsterdam UMC Location Vrije Universiteit Amsterdam University Medical Center Utrecht Utrecht University

About

Marjolijn N. Lub–de Hooge is an author at University Medical Center Groningen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.6K
2	Engineering	6	6	311
3	Health Sciences	5	5	913
4	Cell Biology	5	5	234
5	Biomedical Engineering	2	2	73

Marjolijn N. Lub–de Hooge

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink, Clinical Pharmacology & Therapeutics	2010	792
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge, Nature Medicine Oncologic ImagingPd-l1 BlockadeMedicineImmune Checkpoint InhibitorTherapeutic Imaging	2018	702
Development and Characterization of Clinical-Grade <sup>89</sup>Zr-Trastuzumab for HER2/<i>neu</i> ImmunoPET Imaging Eli Dijkers, Jos G. W. Kosterink, Anna P. Rademaker, Journal of Nuclear Medicine	2009	334
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft Wouter B. Nagengast, Elisabeth G.E. de Vries, Geke A.P. Hospers, Journal of Nuclear Medicine	2007	313
Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Patrick J. Perik, Marjolijn N. Lub–de Hooge, Jourik A. Gietema, Journal of Clinical Oncology	2006	307
Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study Laetitia E. Lamberts, Maximillian Koch, Johannes S. de Jong, Clinical Cancer Research	2016	267
Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis Bouke P. C. Hazenberg, M. H. van Rijswijk, D. Albertus Piers, The American Journal of Medicine Alzheimer's DiseaseDiagnosisPathologyNeurochemical BiomarkersDiagnostic Performance	2006	176
<sup>89</sup>Zr-Bevacizumab PET Imaging in Primary Breast Cancer Sietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, Journal of Nuclear Medicine	2013	161
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity M.A. de Korte, Elisabeth G.E. de Vries, Marjolijn N. Lub–de Hooge, European Journal of Cancer InflammationTrastuzumab-related CardiotoxicityHeart FailureCardiomyopathyStructural Heart Disease	2007	161
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up Frederike Bensch, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, European Journal of Nuclear Medicine and Molecular Imaging	2018	134

Page 1